"Because it inhibits the Bcl-2 proteins associated with poor response to existing therapies for B-cell lymphomas, we expected that venetoclax would have a direct impact on CAR T cell populations ...

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed treatment for a patient with chronic ...

The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated ...

Quality-of-life (QOL) outcomes vary widely for patients receiving first-line treatment for chronic lymphocytic leukemia (CLL) ...

The progression-free survival (PFS) rate at 3 years reached 76.5% with acalabrutinib (Calquence) plus venetoclax (Venclexta), as compared with 66.5% with investigator's choice of standard ...

Pharmac currently funds venetoclax for a different type of blood cancer called chronic lymphocytic leukaemia, and funds upadacitinib for some people with rheumatoid arthritis. Azacitidine is currently ...

The study highlights poor outcomes for leukaemia patients with a history of myelodysplastic syndrome treatment and related ...

has approved the tolerability of the first three patients enrolled in the Phase I/II clinical trial of DFP-10917 in combination with Venetoclax (VEN) (NCT06382168) conducted at five US clinical ...

Aptose Biosciences (APTO) announced dosing the first set of patients in the TUSCANY Phase 1/2 study with tuspetinib in combination with ...

BCL-2 inhibitors, such as venetoclax (Venclexta) work by targeting the BCL-2 protein, which plays a key role in preventing ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...